Invention Grant
- Patent Title: Recombinant FcγRII
-
Application No.: US16335519Application Date: 2017-09-21
-
Publication No.: US11414475B2Publication Date: 2022-08-16
- Inventor: Kouta Hatayama , Teruhiko Ide , Hiroyuki Ito , Yosuke Terao , Naoki Yamanaka , Satoshi Endo
- Applicant: TOSOH CORPORATION , SAGAMI CHEMICAL RESEARCH INSTITUTE
- Applicant Address: JP Yamaguchi; JP Kanagawa
- Assignee: TOSOH CORPORATION,SAGAMI CHEMICAL RESEARCH INSTITUTE
- Current Assignee: TOSOH CORPORATION,SAGAMI CHEMICAL RESEARCH INSTITUTE
- Current Assignee Address: JP Yamaguchi; JP Kanagawa
- Agency: Greenblum & Bernstein, P.L.C.
- Priority: JPJP2016-185717 20160923,JPJP2016-185718 20160923
- International Application: PCT/JP2017/034152 WO 20170921
- International Announcement: WO2018/056374 WO 20180329
- Main IPC: C07K1/00
- IPC: C07K1/00 ; C07K14/735 ; C07K1/22 ; C07K16/06 ; C12N1/20 ; C12N15/70 ; C12P21/02

Abstract:
The problem to be addressed by the present invention is to provide improved recombinant FcγRIIb and FcγRIIa that do not require refolding and exhibit high productivity and thermal stability, and to provide a method for producing the same. Said problem is solved by improved recombinant FcγRIIb comprising at least the amino acid residues of the extracellular domain of human FcγRIIb (No. 43 to No. 215 in UniProt No. P31994), wherein, in said amino acid residues, at least one amino acid substitution has occurred at a position corresponding to No. 82, 94, 98, 104, 105, or 139 in UniProt No. P31994. Said problem is also solved by improved recombinant FcγRIIa comprising at least the amino acid residues of the extracellular domain of human FcγRIIa (No. 34 to No. 206 in UniProt No. P12318-1), wherein, in said amino acid residues, at least one amino acid substitution has occurred at a position corresponding to No. 73, 85, 89, 95, 96, or 130 in UniProt No. P12318-1.
Public/Granted literature
- US20190233499A1 IMPROVED RECOMBINANT FcgammaRII Public/Granted day:2019-08-01
Information query